Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Pacific Biosciences of California (PACB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Pacific Biosciences's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.760 +0.070    +4.14%
02/05 - Closed. Currency in USD ( Disclaimer )
After Hours
1.770
+0.010
+0.557%
0:58:35 - Real-time Data
  • Volume: 9,526,536
  • Bid/Ask: 1.700 / 1.770
  • Day's Range: 1.690 - 1.870
Type:  Equity
Market:  United States
Pacific Biosciences 1.760 +0.070 +4.14%

NASDAQ:PACB Financials

 
This summary provides an overview of the most significant critical numbers from each of the Pacific Biosciences financial reports, including thePacific Biosciences of California income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.

Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the NASDAQ:PACB financials over time via breakdowns of their annual reports.

Pacific Biosciences of California, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 58.36 million compared to USD 27.35 million a year ago. Net loss was USD 82.02 million compared to USD 84.38 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.37 a year ago. Diluted loss per share from continuing operations was USD 0.31 compared to USD 0.37 a year ago.For the full year, revenue was USD 200.52 million compared to USD 128.3 million a year ago. Net loss was USD 306.74 million compared to USD 314.25 million a year ago. Basic loss per share from continuing operations was USD 1.21 compared to USD 1.4 a year ago. Diluted loss per share from continuing operations was USD 1.21 compared to USD 1.4 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

PACB Income Statement & Profits

Gross margin TTM 29.02%
Operating margin TTM -153.07%
Net Profit margin TTM -152.97%
Return on Investment TTM -16.78%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 58.36 55.69 47.57 38.9
Gross Profit 14.99 17.9 15.73 9.94
Operating Income -82.95 -73.78 -71.2 -79
Net Income -82.02 -66.87 -69.83 -88.02

PACB Balance Sheet

Quick Ratio MRQ 7.06
Current Ratio MRQ 7.81
LT Debt to Equity MRQ 127.23%
Total Debt to Equity MRQ 133.17%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 1746.01 1898.35 1847.63 1896.42
Total Liabilities 1044.71 1134.61 1205.63 1204.3
Total Equity 701.3 763.74 642 692.12

%ENGLISH_NAME% Latest Cash Flow Statement

Cash Flow/Share TTM -0.97
Revenue/Share TTM 0.75
Operating Cash Flow  -60.57%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -57.56 -65.18 -41.74 -94.69
Cash From Investing Activities -66.58 242.32 -98.59 -72.55
Cash From Financing Activities -81.6 -0.781 -4.72 195.99
Net Change in Cash -205.74 176.36 -145.05 28.74
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PACB Price Commentary

Write your thoughts about Pacific Biosciences of California
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
optimus kraken
optimus kraken Apr 14, 2022 5:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
penny stock soon
optimus kraken
optimus kraken Mar 19, 2022 18:21
Saved. See Saved Items.
This comment has already been saved in your Saved Items
dead ?!
Ken Laing
Ken Laing May 06, 2021 10:56
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will buy at 20
Kenny Dwyer
Kenny Dwyer May 06, 2021 10:56
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hope you didnt
Ken Laing
Ken Laing May 06, 2021 10:56
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kenny Dwyer I bought CRSP instead, I am down on that too but not as bad as this
Ken Laing
Ken Laing Mar 28, 2021 13:02
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Could be more downside in short term
Charlie palmer
Charlie palmer Mar 14, 2021 17:42
Saved. See Saved Items.
This comment has already been saved in your Saved Items
will be big in future like crispr this biotechnology will be revolutionary
ANDY LEONG
ANDY LEONG Nov 20, 2020 16:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what happen to PACB
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email